Friday, 15th February 31st Lorne Cancer Conference 2019

• New Insights into Endocrine Therapy Resistance in Breast Cancer - Matthew Ellis
• Single cell transcriptome analysis reveals human prostate cancer cells upregulate retinoic acid signalling in response to androgen withdrawal. - Renea Taylor
• Regulation of prostate cancer cell plasticity by microRNAs - Luke Selth
• A phase 1b dose-escalation and expansion study of the BCL-2 inhibitor venetoclax combined with tamoxifen in ER and BCL-2-positive metastatic breast cancer - Sheau Wen Lok
• Chromatin interactome mapping identifies target genes at breast cancer risk signals - Stacey Edwards

• Tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy - Thomas Gajewski
• Immune Checkpoint Inhibition in Prostate Cancer: Challenges and Progress. - Shahneen Sandhu
• Innate immune control of metastatic cancer and priming of T cell anti-tumour immunity  - Nicholas Huntington
• Novel transposon based CART cell therapy for B cell malignancies - Alla Dolnikov
• Targeting the immune microenvironment in breast cancer - Sherene Loi

Friday 15^th February 13:00 – 14:00

Presented by Jessica Duarte, PhD (Olivia Newton-John Cancer Research Institute)

“Immunome arrays: searching for autoantibody biomarkers” 

The IMMUNOME™ v4 Discovery Array is a protein array which utilises the patented Sengenics KREX™ functional proteomics technology. Consisting of 1600+ full-length human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens. The arrays are coated with a proprietary surface which preserves protein folding and inhibits binding of non-specific proteins. RSVP to our workshop and learn about capabilities to discover autoantibody biomarkers for diagnostics, risk of adverse drug reactions, autoantibody-based therapeutic and prophylactic biologics, selectivity screens for new chemical entities and new biologics and functional assays for any protein and any interacting biomolecule.

• What makes a great paper? - Anna Dart

• The role of INPP4B overexpression in breast cancer pathogenesis  - Christina Mitchell
• Molecular Mechanisms of Growth Factor Surveillance - Alexander D Barrow
• Safe targeting of T‐cell acute lymphoblastic leukemia by subunit selective gamma‐secretase inhibition - Charles E de Bock
• BRCA1 promoter methylation and clinical outcomes in epithelial ovarian cancer a pooled analysis of individual patient data - Britta Stordal
• Improving conventional therapy for glioblastoma via cell cycle checkpoint inhibition - Tracy Seymour
• RNA binding kinase UHMK1 regulates therapy induced metabolic adaptation in BRAF^V600 melanoma - Lorey Smith
• Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer - Elaine Sanij
• p53 and Rb Regulate Autophagy, Primary Cilia Formation and Hedgehog Signalling  - Catherine R Cochrane
• Feasibility of a virtual reality intervention for the reduction of parent and patient distress and anaesthesia requirement during paediatric radiation therapy - Nigel Anderson
• DNA barcoding demonstrates immuno-editing of metastatic breast cancer cells at the clonal level - Simon Junankar
•   Monolineage origin of relapse following multilineage differentiation therapy of acute myeloid leukemia. - Steven Ngo
• Protective autophagy elicited in response to RAF→MEK→ERK pathway inhibition suggests a treatment strategy for RAS-driven cancers - Martin McMahon

• Predicting missense mutated p53 functional ability based on structural features. - Malancha Karmakar
• Modelling combinatorial mutations in myeloid leukaemia using zebrafish - Sarada Ketharnathan
• Breast Cancer and Radiolabelling Aptamers for Theranostic Application - umair khalid
• Targeting the achilles' heel of clear cell ovarian cancer - Tashbib Khan
• Diagnosis and disease evolution during immunotherapy - longitudinal profiling of autoantibodies using high-content protein arrays - Gregor S Kijanka
• Therapeutically targeting oncoprotein USP5 in MYCN-driven neuroblastoma - Ane Kleynhans
• Breast cancer metastasis to gynaecological organs – a clinico-pathological and molecular profiling study. - Jamie R Kutasovic
• Isolation and characterisation of viable quiescent cancer cells - Ting La
• The role of Ptp61F in cell competition in cell polarity-impaired epithelial tissues - John E La Marca
• Distinct cancer-promoting stromal gene expression programs depending on lung function - Ola Larsson
• Understanding molecular mechanisms of drug resistance at single cell resolution using biomimetic tissue engineering - Andrew Law
• New patient-derived models for rapid preclinical testing of castration-resistant prostate cancer - Mitchell Lawrence
• Investigating the tumour suppressor functions of p53 - Elizabeth Lieschke
• Improving treatment of brain metastases using theranostic nanomedicines - Malcolm Lim
• Pancreatic cancer organoids and corresponding xenografts: tools to better understand disease progression - Ronnie Ren Jie Low
• A bioinformatic approach to defining the mechanisms of chemoresistance in small cell lung cancer - Quinton Luong
• Antiproliferative and autophagic effects caused by a new 2-quinoxalinyl-hydrazone in colorectal cancer cells - Sarah S Maranhao
• Network of molecular targets in SMA-RL71-treated xenograft model of triple negative breast cancer: a multivariate statistical and data mining analysis - Orleans N.K Martey
• Oral administration of exosomes induce senescence in the primary tumor but accelerates cancer metastases - Suresh Mathivanan
• Targeting cell lineage as a therapeutic strategy to overcome high-risk neuroblastoma - Suresh Mathivanan
• Uncovering the role of alternative splicing in mammary gland development and breast cancer. - Michael Milevskiy
• Relationship between the pentose phosphate pathway and mutant p53 cancer therapies - Julia Milne
• The snake venom-derived disintegrin, Lebein-1, mediates direct anti-tumour and anti-angiogenic activity against metastatic Triple Negative Breast Cancer - Fuentes Miriam
• Therapeutically targeting Myc in gastric cancer - Riley J Morrow
• Personalised medicine approach in pancreatic cancer reveals fine-tuned stromal FAK manipulation to improve global response to gemcitabine and Abraxane - Kendelle J Murphy
• Targeting the tumour vasculature in pancreatic cancer - Kay K Myo Min
• Ferroptosis enhances the efficacy of HER2 targeted therapy against HER2^+ve breast cancer brain metastasis  - Aadya Nagpal
• Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma - Ksenija Nesic
• Loss of Bcl-g predisposes the development of inflammation-associated colorectal cancer - Paul M Nguyen
• Genomic analysis of low-grade serous ovarian cancer reveals unique therapeutic vulnerabilities - Abhimanyu Nigam
• In vivo imaging of Rac1 targeting in metastatic breast cancer - Max Nobis
• Exploiting the cross talk between tuft cells and group 2 innate lymphoid cells for tissue homeostasis and disease - Ryan OKeefe
• Exploiting tumour-intrinsic IFN signalling to predict and prevent prostate cancer progression in bone     - Katie L Owen
• Developing targeted drug delivery for the treatment of melanoma - Amy Oxlade
• Investigating the role of gp130/STAT3 signalling in intestinal barrier function - Lokman Pang
• Preventing tumour growth by reprogramming tumour associated macrophages - Fiona J Pixley
• Using peptide inhibitors to target HSF1 as a novel strategy in cancer metastasis treatment  - Joe Polidano
• Investigating the interplay between 14-3-3ζ and the Rho-ROCK pathway in breast cancer - Valentina Poltavets
• Predicting cancer phenotype from missense mutations in PTEN - Stephanie Portelli
• Improving the diagnosis and treatment of cancers of unknown primary with molecular profiling - Atara Posner
• Translational control of hypoxia-induced breast cancer plasticity - Lynne-Marie Postovit
• Subclinical dose of hydroxyurea sensitises melanomas and non-small cell lung cancers to chk1 inhibitor to effectively control tumour growth and trigger an inflammatory response with reduced normal tissue toxicity - Martina Proctor
• CEP55 depletion can delay tumorigenesis through GSK3β/ β-Catenin/ Myc axis downstream of Akt signaling pathway - Behnam Rashidieh
• Using E-cadherin dynamics and Src activity to predict cancer spread and response to anti-invasive therapies: Insights from intravital imaging - Daniel A Reed
• Characterisation of a novel method of colorectal liver metastasis induction in mice - Georgina E Riddiough
• High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma  - Sewa Rijal
• The role of INPP4B overexpression in breast cancer pathogenesis - Samuel Rodgers
• mCSM-PPI2: a web server for predicting the effects of single-point mutations in protein-protein binding affinity - Carlos HM Rodrigues
• Heparin and heparin derivative (de-2-O-sulfated) change tumour dynamics of B16F10 murine melanoma cells - Gustavo R Rossi
• Natural product derivative nanoformulations with in vitro brain cancer cytotoxic activity - Rebecca H Roubin
• ADAM17/IL-6 trans-signalling axis: A promising therapeutic target for lung adenocarcinoma - Mohamed I. Saad
• Exploring the oncogenic role of splicing associated proteins in MYCN-driven neuroblastoma - Alice Salib
• c-Myc and Metabolic Reprogramming in Liver Cancer - Talhah M Salmi
• Harnessing the full potential of CAR-T cells for improved treatment of solid tumours - Terri Scanlon
• Metabolically Reprograming Pancreatic Stellate Cells using a Novel Nanomedicine for the Treatment of Pancreatic Cancer - George Sharbeen
• βIII-Tubulin is a Brake for External Cell-Death Signalling in Pancreatic Cancer - George Sharbeen
• The multi-faceted efficacy of novel thiosemicarbazone anti-cancer agents in the Treatment of Estrogen Receptor Positive Breast Cancer - Faten Shehadeh Tout
• Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M - Lucy K Shewell
• The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1 - Benjamin J Shields
• Targeted drug delivery to brain metastases - Sarah Shigdar
• Predicting variant pathogenicity and identifying novel functional features in genes and their protein tertiary structures using the Missense Tolerance Ratio - Michael Silk
• The Δ133p53β isoform promotes an immunosuppressive environment leading to aggressive prostate and brain cancers - Tania L Slatter
• Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation and improved overall survival - Eric Smith
• Analysis of antibody-fluorophore conjugate stability in immuno-flowFISH assessment of normal and leukaemia blood samples - Jason Stanley
• Inhibiting lysyl oxidases to reduce fibrotic microenvironment and stroma - Jessica Stolp
• The utility of a HPMA-NIPAM co-polymer as a less-immunogenic alternative to PEGylation as an approach to modify the pharmacokinetic behaviour of antibody therapeutics - Christopher Subasic
• Sex differences in the plasma pharmacokinetics of Caelyx are not observed in relatively healthy individuals: a study in healthy rats and retrospective evaluation in humans - Christopher Subasic
• Modelling the genetic heterogeneity of KRAS-mutant lung adenocarcinomas for therapeutic discovery - Kate D Sutherland
• The control of melanoma metastasis by the YAP oncogene - Pacman Szeto
• CTCF modulates glucocorticoid-induced BIM gene transcription in acute lymphoblastic leukaemia - Xiaolu Tai
• Exploring the binding sites of human ATP- Binding Cassette B5 transporter by molecular docking   - Lokeswari Prathyusha Tangella
• Understanding and overcoming ABCB5 transporter-mediated drug resistance for BRAF inhibitors in cutaneous melanoma - Lokeswari Prathyusha Tangella
• Austocrine Laminin-511 in triple negative breast cancer immunobiology  - Elnaz ET Tavancheh
• Translational control of metabolic plasticity limits the efficacy of anti-cancer therapies. - Ivan Topisirovic
• Identification of novel gp130 inhibitors as potential treatments for colon cancer - Kelly Tran
• miR-21 is a STAT3 driven onco-miR in Gastric cancer - Janson WT Tse
• Characterising changes in ribosomal DNA chromatin during malignant transformation - Thejaani Udumanne
• Inhibition of Hedgehog signalling in ligand dependent tumours - Vijesh Vaghjiani
• Crosstalk between oncogenic signaling pathways reprograms lipid metabolism in cancer - Srimayee Vaidyanathan
• Targeting the cell guidance receptor EphA3 in the inflammatory tumor microenvironment - Mary E Vail
• Understandingthe role of Interleukin-11 in pancreatic ductal adenocarcinoma - Gemma van Duijneveldt
• Disrupting copper homeostasis enhances anti-tumour immune response - Florida Voli
• Detection of N-glycolylneuraminic acid biomarkers in sera from patients with breast cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M - Jackie J Wang
• The role of estrogen in promoting uptake of liposomes by monocytes - Lili Wang
• Lineage specific transcription factors are involved in modulating chromatin accessibility at pro-apoptotic BIM gene locus in ALL - Meng Wang
• Novel Peptide-MHC Chimeric Antigen Receptor T cells for the treatment of Diffuse Midline Glioma - Shiqi Wang
• A novel therapeutic approach to inhibit the oncogenic cross-talk between pancreatic cancer cells and the surrounding stroma - Bekesho G. Wendimu
• Chk1/2 inhibition enhances the efficacy of radiation treatment both in vitro and in vivo in medulloblastoma - Jacqueline Whitehouse
• Activation of nucleolar DNA damage response as a therapeutic strategy for ovarian cancer - Jiachen Xuan
• Targeting activated platelets- An avenue for early cancer detection and targeted treatment. - May Lin Yap
• Intratumoural delivery of an IFN-agonist decreases metastasis and increases survival in murine TNBC - Damien J Zanker
• Identification of novel inhibitors of the cystine-glutamate antiporter SLC7A11 for cancer therapy. - Bonnie Zhang
• Irinotecan hydrochloride and 7-ethyl-10-hydroxycamptothecin based excipient-free nanodispersions have powerful therapeutic potential for pancreatic cancer - Linshi Zhang